miR‑214 targets the PTEN‑mediated PI3K/Akt signaling pathway and regulates cell proliferation and apoptosis in ovarian cancer

Liu,Jing; Chen,Weiyan; Zhang,Haiyan; Liu,Ting; Zhao,Lin

doi:10.3892/ol.2017.6953

miR‑214 targets the PTEN‑mediated PI3K/Akt signaling pathway and regulates cell proliferation and apoptosis in ovarian cancer

Authors:
- Jing Liu
- Weiyan Chen
- Haiyan Zhang
- Ting Liu
- Lin Zhao
View Affiliations

Affiliations: Department of Gynecology, Linyi Tumor Hospital, Linyi, Shandong 276002, P.R. China
Published online on: September 15, 2017 https://doi.org/10.3892/ol.2017.6953
Pages: 5711-5718
Copyright: © Liu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The present study aimed to investigate the potential role of microRNA (miR)‑214 in targeting the phosphatase and tensin homolog (PTEN)‑mediated phosphoinositide 3‑kinase (PI3K)/Akt signaling pathway in ovarian cancer (OC). The target gene of miR‑214 was determined by luciferase reporter gene assay and was indicated to be PTEN. Human SK‑OV‑3 cells were transfected with a miR‑214 inhibitor and a miR‑214 mimic, and reverse transcription‑quantitative polymerase chain reaction (RT‑qPCR) was used to detect relative expression of miR‑214. The MTT assay was performed to detect cell viability following transfection. Cell cycle and apoptosis were assessed by staining with propidium iodide (PI) and double staining with Annexin V/PI, respectively. The expression levels of PTEN and PI3K/Akt signaling pathway‑associated proteins were detected by western blot analysis. The expression of miR‑214 in tumor tissues and normal tissues was detected by RT‑qPCR, and PTEN expression was detected by immunohistochemistry. SK‑OV‑3 cells transfected with a miR‑214 inhibitor showed significantly inhibited cell viability and proliferation, and markedly increased apoptotic rate. SK‑OV‑3 cells transfected with miR‑214 mimic showed significantly increased viability and proliferation, and markedly decreased apoptotic rate. The cells transfected with a miR‑214 inhibitor exhibited significantly upregulated PTEN expression and significantly downregulated phosphatidylinositol (3,4,5)‑trisphosphate (PIP3), phosphorylated (p)‑Akt and p‑glycogen synthase kinase (GSK)‑3β expression. The cells transfected with miR‑214 mimic exhibited significantly downregulated PTEN expression and significantly upregulated PIP3, p‑Akt and p‑GSK‑3β expressions. The OC tissues exhibited an increased expression of miR‑214 and a reduced positive rate of PTEN expression compared with adjacent normal tissues. miR‑214 may activate the PI3K/Akt signaling pathway by downregulating the targeted PTEN, which may promote OC cell proliferation and inhibit apoptosis.

View Figures

View References

1	Siegel R, Naishadham D and Jemal A: Cancer statistics, 2013. CA Cancer J Clin. 63:11–30. 2013. View Article : Google Scholar : PubMed/NCBI
2	Chornokur G, Amankwah EK, Schildkraut JM and Phelan CM: Global ovarian cancer health disparities. Gynecol Oncol. 129:258–264. 2013. View Article : Google Scholar : PubMed/NCBI
3	Lowe KA, Chia VM, Taylor A, O'Malley C, Kelsh M, Mohamed M, Mowat FS and Goff B: An international assessment of ovarian cancer incidence and mortality. Gynecol Oncol. 130:107–114. 2013. View Article : Google Scholar : PubMed/NCBI
4	Chiang YC, Chen CA, Chiang CJ, Hsu TH, Lin MC, You SL, Cheng WF and Lai MS: Trends in incidence and survival outcome of epithelial ovarian cancer: 30-year national population-based registry in Taiwan. J Gynecol Oncol. 24:342–351. 2013. View Article : Google Scholar : PubMed/NCBI
5	Wong KH, Mang OW, Au KH and Law SC: Incidence, mortality, and survival trends of ovarian cancer in Hong Kong, 1997 to 2006: A population-based study. Hong Kong Med J. 18:466–474. 2012.PubMed/NCBI
6	Ledermann JA, Raja FA, Fotopoulou C, Gonzalez-Martin A, Colombo N and Sessa C: ESMO Guidelines Working Group: Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 24 Suppl 6:vi24–vi32. 2013. View Article : Google Scholar : PubMed/NCBI
7	Katz B, Trope CG, Reich R and Davidson B: MicroRNAs in ovarian cancer. Hum Pathol. 46:1245–1256. 2015. View Article : Google Scholar : PubMed/NCBI
8	Davis-Dusenbery BN and Hata A: MicroRNA in Cancer: The involvement of aberrant microRNA biogenesis regulatory pathways. Genes Cancer. 1:1100–1114. 2010. View Article : Google Scholar : PubMed/NCBI
9	Tutar L, Tutar E and Tutar Y: MicroRNAs and cancer; an overview. Curr Pharm Biotechnol. 15:430–437. 2014. View Article : Google Scholar : PubMed/NCBI
10	Xia H, Ooi LL and Hui KM: MiR-214 targets β-catenin pathway to suppress invasion, stem-like traits and recurrence of human hepatocellular carcinoma. PLoS One. 7:e442062012. View Article : Google Scholar : PubMed/NCBI
11	Bar-Eli M: Searching for the ‘melano-miRs’: miR-214 drives melanoma metastasis. EMBO J. 30:1880–1881. 2011. View Article : Google Scholar : PubMed/NCBI
12	Penna E, Orso F, Cimino D, Tenaglia E, Lembo A, Quaglino E, Poliseno L, Haimovic A, Osella-Abate S, De Pittà C, et al: microRNA-214 contributes to melanoma tumour progression through suppression of TFAP2C. EMBO J. 30:1990–2007. 2011. View Article : Google Scholar : PubMed/NCBI
13	Xu Z and Wang T: miR-214 promotes the proliferation and invasion of osteosarcoma cells through direct suppression of LZTS1. Biochem Biophys Res Commun. 449:190–195. 2014. View Article : Google Scholar : PubMed/NCBI
14	Yang Z, Chen S, Luan X, Li Y, Liu M, Li X, Liu T and Tang H: MicroRNA-214 is aberrantly expressed in cervical cancers and inhibits the growth of HeLa cells. IUBMB Life. 61:1075–1082. 2009. View Article : Google Scholar : PubMed/NCBI
15	Yang H, Kong W, He L, Zhao JJ, O'Donnell JD, Wang J, Wenham RM, Coppola D, Kruk PA, Nicosia SV and Cheng JQ: MicroRNA expression profiling in human ovarian cancer: miR-214 induces cell survival and cisplatin resistance by targeting PTEN. Cancer Res. 68:425–433. 2008. View Article : Google Scholar : PubMed/NCBI
16	Gadducci A, Sergiampietri C, Lanfredini N and Guiggi I: Micro-RNAs and ovarian cancer: The state of art and perspectives of clinical research. Gynecol Endocrinol. 30:266–271. 2014. View Article : Google Scholar : PubMed/NCBI
17	Mabuchi S, Kuroda H, Takahashi R and Sasano T: The PI3K/AKT/mTOR pathway as a therapeutic target in ovarian cancer. Gynecol Oncol. 137:173–179. 2015. View Article : Google Scholar : PubMed/NCBI
18	Bai H, Li H, Li W, Gui T, Yang J, Cao D and Shen K: The PI3K/AKT/mTOR pathway is a potential predictor of distinct invasive and migratory capacities in human ovarian cancer cell lines. Oncotarget. 6:25520–25532. 2015. View Article : Google Scholar : PubMed/NCBI
19	Yang X, Cheng Y, Li P, Tao J, Deng X, Zhang X, Gu M, Lu Q and Yin C: A lentiviral sponge for miRNA-21 diminishes aerobic glycolysis in bladder cancer T24 cells via the PTEN/PI3K/AKT/mTOR axis. Tumour Biol. 36:383–391. 2015. View Article : Google Scholar : PubMed/NCBI
20	FIGO Oncology Committee, . FIGO staging for gestational trophoblastic neoplasia 2000. FIGO Oncology Committee. Int J Gynaecol Obstet. 77:285–287. 2002. View Article : Google Scholar : PubMed/NCBI
21	Scully RE and Sobin LH: Histological Typing of Ovarian Tumours. 2nd. Springer Verlag; New York, NY: 1999, View Article : Google Scholar
22	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
23	Penna E, Orso F and Taverna D: miR-214 as a key hub that controls cancer networks: Small player, multiple functions. J Invest Dermatol. 135:960–969. 2015. View Article : Google Scholar : PubMed/NCBI
24	Vara Fresno JA, Casado E, de Castro J, Cejas P, Belda-Iniesta C and González-Barón M: PI3K/Akt signalling pathway and cancer. Cancer Treat Rev. 30:193–204. 2004. View Article : Google Scholar : PubMed/NCBI
25	Li H, Zeng J and Shen K: PI3K/AKT/mTOR signaling pathway as a therapeutic target for ovarian cancer. Arch Gynecol Obstet. 290:1067–1078. 2014. View Article : Google Scholar : PubMed/NCBI
26	Faes S and Dormond O: PI3K and AKT: Unfaithful partners in cancer. Int J Mol Sci. 16:21138–21152. 2015. View Article : Google Scholar : PubMed/NCBI
27	Qiang R, Wang F, Shi LY, Liu M, Chen S, Wan HY, Li YX, Li X, Gao SY, Sun BC and Tang H: Plexin-B1 is a target of miR-214 in cervical cancer and promotes the growth and invasion of HeLa cells. Int J Biochem Cell Biol. 43:632–641. 2011. View Article : Google Scholar : PubMed/NCBI
28	Yin G, Chen R, Alvero AB, Fu HH, Holmberg J, Glackin C, Rutherford T and Mor G: TWISTing stemness, inflammation and proliferation of epithelial ovarian cancer cells through MIR199A2/214. Oncogene. 29:3545–3553. 2010. View Article : Google Scholar : PubMed/NCBI
29	Zaman MS, Maher DM, Khan S, Jaggi M and Chauhan SC: Current status and implications of microRNAs in ovarian cancer diagnosis and therapy. J Ovarian Res. 5:442012. View Article : Google Scholar : PubMed/NCBI
30	Chou J and Werb Z: MicroRNAs play a big role in regulating ovarian cancer-associated fibroblasts and the tumor microenvironment. Cancer Discov. 2:1078–1080. 2012. View Article : Google Scholar : PubMed/NCBI